Connect with us

Business

EMA Grants Nova Mentis Life Sciences Corp’s (OTCMKTS: NMLSF) Fragile X Syndrome Psilocybin Drug Orphan Drug Status

Published

on

Nova Mentis Life Sciences Corp (OTCMKTS: NMLSF) has announced that the European Medicines Agency (EMA) has granted it an Orphan Drug Designations for its novel psilocybin drug for fragile X syndrome (FXS) treatment. FXS is the main genetic cause of autism spectrum disorder (ASD) related symptoms.

Nova Mentis psilocybin drug granted orphan drug status by EMA

The orphan drug designation makes the drug eligible for ten years of market exclusivity, access to grants, scientific advice, and procedural and administrative assistance, access to marketing authorization via a single application, and reduced protocol assistance fees.

CEO & President Will Rascal said, “Orphan Drug designation of our proprietary psilocybin formulation in Europe is a significant milestone on the pathway to drug approval,” says Will Rascan, NOVA’s CEO & President. “This achievement has the potential to rapidly advance our company’s clinical program in Europe with the goal of approval of psilocybin in the treatment of FXS, a major unmet medical need. As a result, Nova intends to move expeditiously to begin a phase 2 study with psilocybin in FXS.”

FXS has no available treatment currently 

FXS has no recognized preventative or treatment strategies currently. Available therapies, which include behavioral and pharmaceutical interventions, are a patchwork of ineffective and hazardous treatments. Psilocybin has the ability to affect the immune system and brain signaling pathways, as well as influence cognition and behavior. Similarly, psilocybin is non-toxic and unlikely to cause negative side effects in humans.

Nova Mentis Scientific Advisory Board Dr. Marvin Hausman commented, “Our proprietary psilocybin drug is being proposed as a novel, first-in-class treatment for fragile X. We have achieved several drug development breakthroughs this year, including a significant therapeutic effect in validated preclinical models of ASD and FXS, identification of an effective dose and no observed psilocybin toxicity. We look forward to working closely with EMA to advance our efforts to receive European regulatory marketing approval for our leading psilocybin drug candidate.”

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

FEATURED STORIES

Business6 hours ago

Tilray Inc (NASDAQ: TLRY) Releases Financial Results For Its Second Quarter

Post Views: 6 Tilray Inc (NASDAQ: TLRY) released the financial results for its second quarter ended November 30, 2021. Moreover,...

Business6 hours ago

Greenlane Holdings Inc (NASDAQ: GNLN) Has Received Approval for Exception on the Prevent All Cigarette Trafficking Act

Post Views: 43 Greenlane Holdings Inc (NASDAQ: GNLN) has received authorization for a regulatory and business exception to the Prevent...

Business7 hours ago

Rubicon Organics Inc (OTCMKTS: ROMJF), CEA Industries Inc (OTCMKTS: SRNA), and the Conservative Broadcast Media Journalism (OTCMKTS: CBMJ) Hire New Executives

Post Views: 36 Rubicon Organics Inc (OTCMKTS: ROMJF) has appointed Julie Lassonde to its Board of Directors after receiving security...

Business7 hours ago

MPX International Corp (OTCMKTS: MPXOF) Receives European Union Good Manufacturing Practises certification

Post Views: 47 MPX International Corp (OTCMKTS: MPXOF) has announced that the Medicines Authority of Malta has given Alphafarma Operations...

Business1 day ago

Demand Brands (OTCMKTS: DMAN) Engages Eisner Amper To Conduct Audits Amidst Its Acquisition of CF3 SPV I, LLC

Post Views: 5 Demand Brands Inc (OTCMKTS: DMAN) recently announced its engagement with Eisner Amper  to offer auditing services in...

Business1 day ago

Digital Asset Monetary Network Inc (OTCMKTS: DATI) Announces Its Partnerships With Dot Hip Hop, LLC Who Are Pioneers in the Domain Name Industry

Post Views: 48 Digital Asset Monetary Network Inc (OTCMKTS: DATI) recently announced that its partners in Dot Hip Hop, LLC,...